Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CX-2029 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| CX-2029 Escalation | EXPERIMENTAL | Dose Escalation and Determination |
| CX-2029 Biomarker | EXPERIMENTAL | Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types |
| CX-2029 Expansion | EXPERIMENTAL | Evaluate antitumor activity of CX-2029 |
| Name | Type | Description |
|---|---|---|
| CX-2029 | DRUG | CX-2029 Monotherapy |
Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable tumors 2. Patients demonstrating disease progression after treatment with approved therapies that are known to confer life-prolonging benefit, or who are intolerant to or have d...
CX-2029 is an investigational small molecule being studied for the treatment of adult patients with solid tumors, including head and neck cancer, non-small cell lung cancer, and esophageal cancer, as well as diffuse large B cell lymphoma. It is currently in Phase 1 clinical development.
CX-2029 is being developed by CytomX Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CTMX. The company is conducting clinical trials to evaluate the safety and activity of this investigational drug.
CX-2029 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed to evaluate safe and active doses in patients with certain solid tumors or diffuse large B cell lymphoma.
CX-2029 has been studied in a Phase 1 clinical trial with the identifier NCT03543813, titled PROCLAIM-CX-2029. This completed trial enrolled 133 participants and was conducted in the United States, South Korea, Spain, and the United Kingdom.
No, CX-2029 is the investigational drug, while PROCLAIM-CX-2029 is the name of the clinical trial studying it. The trial, identified as NCT03543813, was designed to find safe and active doses of CX-2029 for patients with solid tumors or diffuse large B cell lymphoma.